Skip to main content
Premium Trial:

Request an Annual Quote

Amersham Pharmacia Biotech Will Acquire Molecular Dynamics

Premium

SUNNYVALE, Calif.--Amer sham Pharmacia Biotech, the joint venture between Nycomed Amersham and Pharmacia & Upjohn, and its strategic partner here, Molecu lar Dynamics, entered into a merger agreement providing for the acquisition of Molecular Dynamics by Amer sham.

The companies claimed the acquisition will strengthen Amersham's competitive position in the market for DNA sequencing and genomic analysis. Under terms of the agreement, Amersham will initiate a cash tender offer of $20.50 per Molecular Dynamics share, thereby valuing the entire, fully diluted Molecular Dynamics' share capital at approximately $256 million.

The two companies formed a strategic alliance in 1994 that has brought together the molecular biology and chemistry skills of Amersham with the instrumentation and software capabilities of Molecular Dynamics to develop and market complete DNA sequencing and genomic analysis systems.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.